Abstract
Introduction:
This guideline establishes clinical practice recommendations for the management of rapid eye movement sleep behavior disorder (RBD) in adults.
Methods:
The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths based on a systematic review of the literature and an assessment of the evidence using Grading of Recommendations, Assessment, Development and Evaluation methodology. The task force provided a summary of the relevant literature and the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations. The AASM Board of Directors approved the final recommendations.
Good Practice Statement:
The following good practice statement is based on expert consensus, and its implementation is necessary for the appropriate and effective management of patients with RBD: It is critically important to help patients maintain a safe sleeping environment to prevent potentially injurious nocturnal behaviors. In particular, the removal of bedside weapons, or objects that could inflict injury if thrown or wielded against a bed partner, is of paramount importance. Sharp furniture like nightstands should be moved away or their edges and headboard should be padded. To reduce the risk of injurious falls, a soft carpet, rug, or mat should be placed next to the bed. Patients with severe, uncontrolled RBD should be recommended to sleep separately from their partners, or at the minimum, to place a pillow between themselves and their partners.
Recommendations:
The following recommendations, with medications listed in alphabetical order, are a guide for clinicians in choosing a specific treatment for RBD in adults. Each recommendation statement is assigned a strength (“strong” or “conditional”). A “strong” recommendation (ie, “We recommend…”) is one that clinicians should follow under most circumstances. A “conditional” recommendation (ie, “We suggest…”) is one that requires that the clinician use clinical knowledge and experience and strongly consider the patient’s values and preferences to determine the best course of action.
Adult patients with isolated RBD
-
1.
The AASM suggests that clinicians use clonazepam (vs no treatment) for the treatment of isolated RBD in adults. (CONDITIONAL)
-
2.
* The AASM suggests that clinicians use immediate-release melatonin (vs no treatment) for the treatment of isolated RBD in adults. (CONDITIONAL)
-
3.
* The AASM suggests that clinicians use pramipexole (vs no treatment) for the treatment of isolated RBD in adults. (CONDITIONAL)
-
4.
The AASM suggests that clinicians use transdermal rivastigmine (vs no treatment) for the treatment of isolated RBD in adults with mild cognitive impairment. (CONDITIONAL)
Adult patients with secondary RBD due to medical condition
-
5.
* The AASM suggests that clinicians use clonazepam (vs no treatment) for the treatment of secondary RBD due to medical condition in adults. (CONDITIONAL)
-
6.
* The AASM suggests that clinicians use immediate-release melatonin (vs no treatment) for the treatment of secondary RBD due to medical condition in adults. (CONDITIONAL)
-
7.
The AASM suggests that clinicians use transdermal rivastigmine (vs no treatment) for the treatment of secondary RBD due to medical condition (Parkinson disease) in adults. (CONDITIONAL)
-
8.
* The AASM suggests that clinicians not use deep brain stimulation (DBS; vs no treatment) for the treatment of secondary RBD due to medical condition in adults. (CONDITIONAL)
Adult patients with drug-induced RBD
-
9.
* The AASM suggests that clinicians use drug discontinuation (vs drug continuation) for the treatment of drug-induced RBD in adults. (CONDITIONAL)
* The Recommendations section of this paper includes remarks that provide additional context to guide clinicians with implementation of this recommendation.
Citation:
Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: An American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2023;19(4):759–768.
Similar content being viewed by others
Abbreviations
- AASM:
-
American Academy of Sleep Medicine
- DBS:
-
deep brain stimulation
- DLB:
-
dementia with Lewy bodies
- MCI:
-
mild cognitive impairment
- PD:
-
Parkinson disease
- PSG:
-
polysomnography
- RBD:
-
rapid eye movement sleep behavior disorder
- REM:
-
rapid eye movement
- RLS:
-
restless legs syndrome
- TF:
-
task force
- 5-HT RBD:
-
5-hydroxytryptamine (serotonergic) RBD
REFERENCES
Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.
Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2023;19(4):769–810.
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.
Morgenthaler TI, Deriy L, Heald JL, Thomas SM. The evolution of the AASM clinical practice guidelines: another step forward. J Clin Sleep Med. 2016;12(1):129–135.
Howell MJ. Rapid eye movement sleep behavior disorder and other rapid eye movement parasomnias. Continuum (Minneap Minn). 2020;26(4):929–945.
Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med. 2013;9(5):475–480.
Haba-Rubio J, Frauscher B, Marques-Vidal P, et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. Sleep. 2018;41(2):zsx197.
Teman PT, Tippmann-Peikert M, Silber MH, Slocumb NL, Auger RR. Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep Med. 2009;10(1):60–65.
Ju YE. Rapid eye movement sleep behavior disorder in adults younger than 50 years of age. Sleep Med. 2013;14(8):768–774.
Tabatabai GM, Boeve AR, Commers N, et al. Time course for phenoconversion to a defined neurodegenerative disease in women with idiopathic REM sleep behavior disorder with and without antidepressant use. (S14.007). Neurology. 2017;88(16 Supplement):S14.007.
Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293–308.
2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–694.
Arnaldi D, Latimier A, Leu-Semenescu S, Vidailhet M, Arnulf I. Loss of REM sleep features across nighttime in REM sleep behavior disorder. Sleep Med. 2016;17:134–137.
Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19(2):153–157.
Brunetti V, Losurdo A, Testani E, et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res. 2014;11(3):267–273.
Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder. Nat Rev Dis Primers. 2018;4(1):19.
Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015;72(6):707–712.
Huecker MR, Smiley A, Saadabadi A. Bupropion. Treasure Island, FL: StatPearls Publishing; 2021.
Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84(11):1104–1113.
Chiong W, Tsou AY, Simmons Z, Bonnie RJ, Russell JA; on behalf of the Ethics, Law, and Humanities Committee (a joint committee of the American Academy of Neurology, American Neurological Association, and Child Neurology Society). Ethical considerations in dementia diagnosis and care. Neurology. 2021;97(2):80–89.
McCarter SJ, Boeve BF, Graff-Radford NR, Silber MH, St. Louis EK. Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise? Sleep. 2019;42(6):zsz064.
ACKNOWLEDGMENTS
The task force thanks and acknowledges the early contributions of Jonathan Heald, MA, a former AASM employee. The task force thanks and acknowledges the contributions of Michael Belleville and Raymond Merrell, who served as patient representatives for this guideline. The task force also thanks Isabelle Arnulf, MD, PhD (Pitié-Salpêtrière Hospital, Paris, France); Madeleine Grigg-Damberger, MD (University of New Mexico School of Medicine, Albuquerque, NM); and Joyce Lee-Iannotti, MD (Banner - University Medical Center, Phoenix, AZ) for serving as external reviewers of this document and providing valuable feedback. The guideline was endorsed by the International RBD Study Group, Project Sleep, and Wake Up Narcolepsy and affirmed by the American Academy of Neurology and the American Geriatrics Society.
Author information
Authors and Affiliations
Corresponding author
Additional information
Address correspondence to: Michael Howell, MD, Department of Neurology, University of Minnesota, 516 Delaware Street SE, Minneapolis, MN 55455; Email: howel020@umn.edu
Rights and permissions
About this article
Cite this article
Howell, M., Avidan, A., Foldvary-Schaefer, N. et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 19, 759–768 (2023). https://doi.org/10.5664/jcsm.10424
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.5664/jcsm.10424

